2010 AAO-MEACO meeting focuses on genetic medicine Oct.

Seeking Genetics-Specific Treatments for Age-Related Macular Degeneration During the past decade ophthalmologists gained a robust tool to control vision-damaging wet age-related macular degeneration : anti-vascular endothelial growth aspect medications. Anti-VEGF medications halt or reverse harm in many wet AMD patients also, but some usually do not respond aswell to treatment and so suffer severe vision loss. The new field of pharmacogenetics seeks to enable doctors to individualize treatment based on the patient’s genetic profile for an illness. In a collaborative work, the Hussman Institute for Human Genomics and Bascom Palmer Eyesight Institute at the University of Miami Miller College of Medicine studied whether specific genetic AMD risk elements and/or smoking influenced patients’ responses to anti-VEGF treatment.Hospitals are displaying a committed action to quality improvement, transparency and individual empowerment by voluntarily releasing discharge medication data from the NCDR's ICD Registry, which tracks techniques to correct abnormal center rhythms, and CathPCI Registry, which tracks procedures to open up blocked or narrow arteries providing blood to the heart. All data is certainly anonymous and does not identify individuals by name. Related StoriesChildren's Memorial Hermann Hospital offers Halloween basic safety tipsPatients offered animal-assisted therapy at UCLA HealthStudy: Post medical center syndrome is significant risk aspect for individuals undergoing elective surgeryBoth patients who receive an implantable cardioverter defibrillator, or ICD, and who undergo percutaneous coronary intervention, or PCI, are prescribed specific medications to safeguard against further heart complications post-procedure.